ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ULVR Unilever Plc

4,073.00
210.00 (5.44%)
Last Updated: 12:13:18
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Unilever Plc LSE:ULVR London Ordinary Share GB00B10RZP78 ORD 3 1/9P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  210.00 5.44% 4,073.00 4,073.00 4,074.00 4,088.00 4,001.00 4,047.00 2,692,615 12:13:18
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Perfume,cosmetic,toilet Prep 59.6B 6.49B 2.5958 15.65 101.54B
Unilever Plc is listed in the Perfume,cosmetic,toilet Prep sector of the London Stock Exchange with ticker ULVR. The last closing price for Unilever was 3,863p. Over the last year, Unilever shares have traded in a share price range of 3,680.50p to 4,483.00p.

Unilever currently has 2,499,017,983 shares in issue. The market capitalisation of Unilever is £101.54 billion. Unilever has a price to earnings ratio (PE ratio) of 15.65.

Unilever Share Discussion Threads

Showing 2076 to 2096 of 3075 messages
Chat Pages: Latest  87  86  85  84  83  82  81  80  79  78  77  76  Older
DateSubjectAuthorDiscuss
19/1/2022
13:31
shorts closing
retsius
19/1/2022
13:24
here is Lex's take (FT)
partenope
19/1/2022
12:42
If they have good news they may well bring the results forward
spoole5
19/1/2022
12:32
back over £36 at least. i bought these for £42 in May 21 and they are the largest holding in my core portfolio. I'm not exactly delighted with recent events to put it very mildly. I am a holder though and have full confidence that the deal is stone dead in the water now and the shares will recover. I like the present mix of brands and would much prefer them to either stick with them with additions made as and when (ie no mega deal) or to have a friendly merger with RKT. I think both the under-performing CEOs could then leave the party with their reputations improved - and Dave Lewis could take over as boss.

Or is this sheer fantasy? :)

partenope
19/1/2022
12:06
P&G out with decent results, raising f/c. this is what unilever should be aiming for. they update in february.
roguetraderuk
19/1/2022
10:50
The logistics and distribution networks of companies such as Unilever and Glaxo are huge.

They are operating in many global counties.
There is duplication of effort, employment and distribution infrastructure.
20 times earnings sounds expensive but synergies will reduce this significantly.

It is easy for us to assume that the Unilever board and its CEO are idiots.
But try to imagine that they are very smart, and that they have been discussing this daily for months and know every detail of risks and potential rewards.

They will not want to go ahead with a wealth destroying bid, or would be allowed to.

careful
19/1/2022
10:49
Dave Lewis as new CEO?.

Every little helps etc ).

Not taken another major role since TSCO.

essentialinvestor
19/1/2022
10:47
rogue, now sitting at a 20/5% plus discount to peer group.

That discounts a hell of a lot,barring something sensationally bad on current trading.

essentialinvestor
19/1/2022
10:43
Whilst it is true that health spending is a growth area, not sure it reads across to toothpaste and painkillers?
rogerrail
19/1/2022
10:40
brwo, its 20 times earnings they are paying. a higher multiple than what they trade at. if you are doing that, you should expect higher growth too. but it hasnt produced it and isnt forecast to either, the gsk figures show it in black and white. its a mystery why gsk didnt accept but i expect its the american partner that is blinkered by higher valuations in the states.
roguetraderuk
19/1/2022
10:37
EI, i would be confident of saying something on that subject after the trading update next month. not before.
roguetraderuk
19/1/2022
10:25
Why make an acquisition if you are not going to get it on the cheap? I fail to see the point in buying something that just may show its value in 5 years. That link to the seeking alpha article was on the money. Nearly all acquisitions are bad deals for the acquirer.
brwo349
19/1/2022
10:08
Jope about to pull it ?
philanderer
19/1/2022
09:34
Just a bunch of over excited traders tying to make a quick buck.
CEO will talk to his serious large investors.
They will decide.

Deals like this take a 20 year view.
Serious investors know that.
The key to this is synergies.

We are so used to profitless Tesla rising 40% in 1 week or worthless Bitcoin doubling and halving over a few weeks that we seem to forget that there are huge important long term businesses out there.

careful
19/1/2022
09:06
He would be a fool to go forward with this deal, the market has spoken.
nick100
19/1/2022
08:55
I think most have concluded the deal is dead in the water. The issue is now one of competence.
pander45
19/1/2022
08:53
They'll not want to lose face... maybe make another half hearted offer knowing it'll be rejected and then pull out?
kiwi2007
19/1/2022
08:50
If they bid another 5 to 10 billion, I think these will go under 3000p.
montyhedge
19/1/2022
08:44
Sold my GSK, it's just whether it's a wise move popping the proceeds in here...
uppompeii
19/1/2022
08:12
Unless they're still determined to go ahead?
bluemango
19/1/2022
08:06
Time to go long Ulvr, short GSK
big7ime
Chat Pages: Latest  87  86  85  84  83  82  81  80  79  78  77  76  Older

Your Recent History

Delayed Upgrade Clock